Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1997-06-25
1998-07-28
Dees, Jose G.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
544237, A61K 31495, C07D40312
Patent
active
057863563
ABSTRACT:
The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective .beta.3 adrenergic receptor agonists useful in the treatment of Type II diabetes and obesity. The invention provides compounds and method of treating type II diabetes, comprising administering to a mammal in need thereof compounds of the Formulas I and II: ##STR1##
REFERENCES:
patent: 4032575 (1977-06-01), Ikezaki et al.
patent: 4288452 (1981-09-01), Sombroek et al.
patent: 4309443 (1982-01-01), Smith et al.
patent: 4338333 (1982-07-01), Ainsworth et al.
patent: 4346093 (1982-08-01), Friebe et al.
patent: 4367235 (1983-01-01), Ross et al.
patent: 4385066 (1983-05-01), Ainsworth et al.
patent: 4391826 (1983-07-01), Mills et al.
patent: 4396627 (1983-08-01), Ainsworth et al.
patent: 4432993 (1984-02-01), Ferris
patent: 4478849 (1984-10-01), Ainsworth et al.
patent: 4497813 (1985-02-01), Ostermayer et al.
patent: 4503067 (1985-03-01), Wiedemann et al.
patent: 4513001 (1985-04-01), Joannic et al.
patent: 4636511 (1987-01-01), Ostermayer et al.
patent: 4652679 (1987-03-01), Alig et al.
patent: 4697022 (1987-09-01), Leinert
patent: 4727067 (1988-02-01), Ostermayer et al.
patent: 4751246 (1988-06-01), Philion
patent: 4772631 (1988-09-01), Holloway et al.
patent: 4892886 (1990-01-01), Alig et al.
patent: 4940800 (1990-07-01), Bertolini et al.
patent: 4960783 (1990-10-01), Bonse et al.
patent: 4977148 (1990-12-01), Holloway et al.
patent: 5013761 (1991-05-01), Beedle et al.
patent: 5064863 (1991-11-01), Alig et al.
patent: 5166218 (1992-11-01), Alig et al.
patent: 5254595 (1993-10-01), Guzzi et al.
patent: 5321036 (1994-06-01), Sher
patent: 5393772 (1995-02-01), Yue et al.
patent: 5420294 (1995-05-01), Beedle et al.
patent: 5453436 (1995-09-01), Ohlstein
patent: 5534640 (1996-07-01), Tegeler et al.
patent: 5541197 (1996-07-01), Fisher et al.
patent: 5541204 (1996-07-01), Sher et al.
patent: 5561142 (1996-10-01), Fisher et al.
patent: 5574164 (1996-11-01), Tegeler et al.
Tejani-Butt and Brunswick. "Synthesis an .beta.-Adrenergic Receptor Blocking Potency of 1-(Substituted amino)-3-(4-indolyloxy)propan-2-ols" J. Med. Chem. 29:1524-1527 (1986).
Burgisser, et al. "Alternative Explanation for the Apparent `Two-Step` Binding Kinetics of High-Affinity Racemic Antagonist Radioligands" Molecular Pharmacology 19:509-512 (1981).
Marinetti, et al. "Beta-Adrenergic Receptors of Human Leukocytes" Biochemical Pharmacology 32(13):2033-2043 (1983).
Howe, et al. "Selective b3-adrenergic agonists of brown adipose tissue and thermogenesis" J. Pharmacology 117:69. Abstrct 40209r (1992).
Bell Michael Gregory
Crowell Thomas Alan
Matthews Donald Paul
McDonald, III John Hampton
Neel David Andrew
Boone David E.
Dees Jos,e G.
Eli Lilly and Company
Lutz Laura R. C.
Skelton Jeffrey J.
LandOfFree
Selective .beta.3 adrenergic agonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Selective .beta.3 adrenergic agonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Selective .beta.3 adrenergic agonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-23841